NYSE — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.novonordisk.comNovo Nordisk A/S has completed the clinical trial for RYBELSUS®, aligned with its ongoing investigation of the investigational drug NNC4004-0002, which is designed to lower serum uric acid in participants with asymptomatic hyperuricemia. This trial, registered as NCT06859073, is still in its recruiting phase and will analyze the drug's safety and tolerance following administration. The study is expected to span approximately 19 months, involving around 60 participants. The findings may have implications for treating conditions related to elevated uric acid levels.
Clinical Trial CompletionNovo Nordisk A/S is expected to complete its clinical trial for the investigational drug Inno8 on September 4, 2025. This Phase 1 study aims to assess the safety of Inno8 in healthy men to support its future development for treating Haemophilia A. The trial is divided into two parts: a single ascending dose (SAD) and a multiple ascending dose (MAD), with a total enrollment of 92 participants. The SAD part involves a single injection of Inno8 or placebo, while the MAD part consists of 1-2 daily tablets over 10 days. Currently, the study is in the recruiting phase, having started in September 2024.
Clinical Trial CompletionNovo Nordisk A/S is conducting a clinical trial titled "Prevalence of Weight Related Complications Across Diverse Weight Classifications," which is expected to finish on October 15, 2025. This study aims to investigate the prevalence of weight-related health issues among various weight categories in individuals from India, Pakistan, the Philippines, and Vietnam. The trial has commenced enrollment by invitation and will include approximately 1,165 participants, who will continue their standard care without receiving any study-specific treatments. The trial has been ongoing since March 17, 2025, and aims to enhance understanding of weight-related health challenges in these populations.
Clinical Trial CompletionNovo Nordisk A/S is conducting a clinical trial to evaluate the safety of NNC4004-0002, an investigational drug aimed at lowering serum uric acid in adults with asymptomatic hyperuricemia. The trial, which has an expected completion date of July 7, 2026, will be conducted in two groups receiving either the study medicine or saline, with a total enrollment of 60 participants. The study will test the drug for safety and tolerability after a single subcutaneous dose, marking the first time it will be administered to humans. The trial began recruitment on November 13, 2024, and includes approximately 14 clinic visits for participants over around 19 months.
Clinical Trial CompletionNovo Nordisk A/S is expected to complete its clinical trial for investigational drug NNC4004-0002 on July 7, 2026. The trial, aimed at evaluating the safety of the drug in adults with asymptomatic hyperuricemia, began on November 13, 2024, and will enroll 60 participants. NNC4004-0002 is intended to assess its effectiveness in lowering serum uric acid. This is the first time the drug will be administered to humans, with the study being in Phase 1 of clinical development.
Clinical Trial CompletionNovo Nordisk A/S is set to complete the clinical trial evaluating its investigational drug NNC4004-0002 on July 7, 2026. The trial focuses on participants with asymptomatic hyperuricemia and aims to assess the drug's safety and tolerability after administration. This is the first human trial for NNC4004-0002, designed to test its effectiveness in lowering serum uric acid levels. Recruitment is currently ongoing, with an expected enrollment of 60 participants. As NNC4004-0002 has not yet received regulatory approval, its use in this trial remains experimental.
Expected Trial Completion DateNovo Nordisk A/S expects to complete the Phase 3 ARTEMIS clinical trial evaluating ziltivekimab for treating patients who have experienced a heart attack by September 3, 2026. The study aims to determine if ziltivekimab can reduce the incidence of heart disease and prevent further cardiovascular events, such as heart attacks and strokes. The trial will involve 10,000 participants and will compare ziltivekimab, an unapproved medication, against a placebo. The trial is currently recruiting, with the expected enrollment starting June 25, 2024. More details are available at the clinical trial registry.
Clinical Trial Expected CompletionNovo Nordisk A/S expects to complete a clinical trial investigating the efficacy of semaglutide for weight loss in children and teenagers on December 7, 2026. The study will compare the weight loss effects of semaglutide against a placebo in a group of 210 participants over approximately 2.5 years. Semaglutide is an approved medication used for type 2 diabetes and weight management in adults, and this research aims to assess its potential benefits for younger populations. The trial began on July 7, 2023, and is currently active but not recruiting new participants.
clinical trial completionNovo Nordisk A/S is expected to complete the SCALE KIDS clinical trial on January 15, 2027. This observational study evaluates the effectiveness of liraglutide, a medication that has previously been prescribed for weight management in adults, for weight loss in children suffering from obesity. The trial, which began on March 4, 2021, aims to assess the drug's impact on body weight and any potential side effects. The 96-week study will involve 78 participants, who will either receive liraglutide or a placebo, alongside guidance on healthy lifestyle choices. The trial is currently listed as active but not recruiting.
Clinical Trial CompletionNVO is expected to complete a clinical trial evaluating semaglutide, a GLP-1 receptor agonist, in reducing gastrointestinal (GI) mucositis in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). The trial, led by Klaus Gottlob Müller and located at Rigshospitalet, Denmark, is set to finish on February 1, 2027. It aims to assess the effect of semaglutide on gut barrier injury and systemic inflammation, with a total of 40 patients planned for randomization in a double-blind, placebo-controlled, phase 2 study. The overall status of the trial is currently 'not yet recruiting' with an anticipated start date of August 12, 2024.
Clinical Trial Completion